IL270576B - Hetero-aromatic-aniline compounds for the treatment of skin disorders - Google Patents

Hetero-aromatic-aniline compounds for the treatment of skin disorders

Info

Publication number
IL270576B
IL270576B IL270576A IL27057619A IL270576B IL 270576 B IL270576 B IL 270576B IL 270576 A IL270576 A IL 270576A IL 27057619 A IL27057619 A IL 27057619A IL 270576 B IL270576 B IL 270576B
Authority
IL
Israel
Prior art keywords
treatment
fused heteroaromatic
aniline compounds
dermal disorders
dermal
Prior art date
Application number
IL270576A
Other languages
English (en)
Hebrew (he)
Original Assignee
Nflection Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nflection Therapeutics Inc filed Critical Nflection Therapeutics Inc
Publication of IL270576B publication Critical patent/IL270576B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
IL270576A 2017-05-19 2019-11-11 Hetero-aromatic-aniline compounds for the treatment of skin disorders IL270576B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762508997P 2017-05-19 2017-05-19
PCT/US2018/033544 WO2018213807A1 (en) 2017-05-19 2018-05-18 Fused heteroaromatic-aniline compounds for treatment of dermal disorders

Publications (1)

Publication Number Publication Date
IL270576B true IL270576B (en) 2022-01-01

Family

ID=62620965

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270576A IL270576B (en) 2017-05-19 2019-11-11 Hetero-aromatic-aniline compounds for the treatment of skin disorders

Country Status (13)

Country Link
US (2) US10988483B2 (https=)
EP (1) EP3624795B1 (https=)
JP (1) JP7237941B2 (https=)
KR (1) KR102659322B1 (https=)
CN (1) CN111093658B (https=)
AU (1) AU2018270292B2 (https=)
CA (1) CA3063535A1 (https=)
DK (1) DK3624795T3 (https=)
ES (1) ES2913213T3 (https=)
IL (1) IL270576B (https=)
MA (1) MA49140A (https=)
MX (1) MX2019013562A (https=)
WO (1) WO2018213807A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7237941B2 (ja) * 2017-05-19 2023-03-13 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置用の融合複素環式芳香族アニリン化合物
CA3120351A1 (en) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
WO2020106308A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
WO2020106306A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
WO2020106305A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
EP4233834A3 (en) * 2018-11-20 2023-10-25 NFlection Therapeutics, Inc. Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
WO1998027980A2 (en) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7674907B2 (en) 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
JP5710855B2 (ja) 2005-02-02 2015-04-30 ネクスジェニクス・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー 神経線維腫の局所治療
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
GB0601962D0 (en) * 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
GB0616214D0 (en) 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
ES2528797T3 (es) * 2006-08-21 2015-02-12 Genentech, Inc. Compuestos de aza-benzotiofenilo y métodos de uso
AU2007286808B2 (en) * 2006-08-21 2012-12-06 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
EP2089359A2 (en) 2006-10-31 2009-08-19 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
PE20081354A1 (es) 2006-11-30 2008-11-14 Genentech Inc Compuestos de azaindolilo como inhibidores de mek
US20080312307A1 (en) 2007-05-25 2008-12-18 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
GB0714384D0 (en) * 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
CA2708176A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
EP2240494B1 (en) 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors
GB0801081D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0801080D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
JP2010043019A (ja) 2008-08-12 2010-02-25 Taisho Pharmaceutical Co Ltd ピペリジニルピペラジン化合物
AR082453A1 (es) 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
WO2012040636A2 (en) 2010-09-24 2012-03-29 The Broad Institute, Inc. Compounds and methods for treating diseases mediated by protease activated receptors
WO2014179785A1 (en) 2013-05-03 2014-11-06 Inscent, Inc. Improved honeybee repellents and uses thereof
CN105384754B (zh) 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
PT3624796T (pt) 2017-05-19 2025-06-02 Nflection Therapeutics Inc Compostos de pirrolopiridina-anilina para tratamento de distúrbios dérmicos
JP7237941B2 (ja) 2017-05-19 2023-03-13 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置用の融合複素環式芳香族アニリン化合物

Also Published As

Publication number Publication date
US11542271B2 (en) 2023-01-03
CA3063535A1 (en) 2018-11-22
US20210380601A1 (en) 2021-12-09
CN111093658B (zh) 2022-10-14
US10988483B2 (en) 2021-04-27
CN111093658A (zh) 2020-05-01
US20200172550A1 (en) 2020-06-04
MA49140A (fr) 2020-03-25
EP3624795B1 (en) 2022-04-20
EP3624795A1 (en) 2020-03-25
JP7237941B2 (ja) 2023-03-13
WO2018213807A1 (en) 2018-11-22
JP2020520994A (ja) 2020-07-16
KR20200026812A (ko) 2020-03-11
MX2019013562A (es) 2020-08-03
DK3624795T3 (da) 2022-05-23
ES2913213T3 (es) 2022-06-01
AU2018270292A1 (en) 2019-12-05
KR102659322B1 (ko) 2024-04-22
AU2018270292B2 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
IL270752B (en) Pyrrolopyridine-aniline compounds for the treatment of skin disorders
SMT201900172T1 (it) Ammino triazoli sostituiti utili come inibitori della chitinasi umana
IL252309B (en) Compressed bicyclic compounds for disease treatment
IL252849B (en) Compressed bicyclic compounds for disease treatment
IL270576B (en) Hetero-aromatic-aniline compounds for the treatment of skin disorders
IL258032A (en) Compounds and preparations for the treatment of ocular disorders
GB201608046D0 (en) Treatment of complement-mediated disorders
SG11201608729RA (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
IL258593B (en) Compounds for the treatment of subculture disorders
ZA202002993B (en) Compounds for the treatment of neuromuscular disorders
SI3302573T1 (sl) Sestavek za zdravljenje možganskih lezij
IL269604A (en) Pentides for the treatment of autoimmune diseases
ZA201705847B (en) Treatment of pain
GB201612043D0 (en) Composition for treatment of disorders
IL254572A0 (en) Compressed bicyclic compounds for disease treatment
PT3458067T (pt) Tratamento de distúrbios neurológicos
GB201607388D0 (en) Treatment of impulsivity-related disorders
IL263177A (en) Fused bicyclic compounds for the treatment of disease
GB201604359D0 (en) Treatment of tissue disorders
HK40026704A (en) Pyrrolopyridine-aniline compounds for treatment of dermal disorders
PT3724173T (pt) Compostos para o tratamento de distúrbios neuromusculares
GB201602784D0 (en) New treatment of CFTR-related disorders
HK40010577A (en) Pparϒ agonist for treatment of bone disorders
HK40006458A (en) Treatment of complement-mediated disorders
GB201506228D0 (en) Methods For The Treatment Of Cardivascular Disorders